HTN Treatment Updates Flashcards

1
Q

ACEI, ARB, direct renin inhibitor (DRI) interactions

A

Aliskiren in the evaluation of proteinuria in diabetes (AVOID) trial: Combination therapy consisting of losartan 100 mg/d and aliskiren (150 mg/d for 3 months and 300 mg/d for 3 months) was minimally beneficial compared with lone losartan therapy in patients with diabetes mellitus type 2 and hypertension (reduction in BP (−2/1 mm Hg), decrease in eGFR decline (−3.8 vs. −2.4 mL/min/1.73 m2), and 20% reduction in albumin to creatinine ratio) at the expense of higher rate of hyperkalemia, 4.7% versus 17%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ACEI, ARB, direct renin inhibitor (DRI) interactions

A

Aliskiren in Type 2 Diabetes Using Cardio–Renal Endpoints (ALTITUDE) trial: Patients with diabetic kidney disease receiving combination therapy with aliskiren and either an ACEI or ARB had reduced proteinuria and SBP by 1 to 2 mm Hg compared with those receiving lone ACEI or ARB therapy at the expense of 25% greater stroke rate and more frequent hyperkalemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ACEI, ARB, direct renin inhibitor (DRI) interactions

A

Over suppression of RAAS leads to worse outcome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Body mass index: Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic HTN (ACCOMPLISH) trial:

A

ACCOMPLISH trial suggests the preferential addition of a CCB over a diuretic to an ACEI in the treatment of HTN in normal-weight patients for improved cardiovascular benefits. In obese high-risk hypertensive patients, however, the choice of adding either a diuretic versus CCB to an ACEI is less important.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Body mass index: Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic HTN (ACCOMPLISH) trial:

A

Proposed mechanism for observed difference: Compared to obese patients, lean individuals are thought to have more prominent RAAS and SNS activities. The use of diuretic in lean patients could further stimulate RAAS and lead to worse cardiovascular outcomes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Renal denervation for resistant HTN:

A

Interruption of renal artery afferent signals (i.e., sympathetic stimulation) to brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Renal denervation for resistant HTN:

A

Simplicity HTN-3 trial: no benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Renal denervation for resistant HTN:

A

Concerns regarding procedure:

May promote renal artery atherogenesis

Interference with denervated kidney ability to tolerate insults such as volume depletion, infection, trauma, drug exposures.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Chlorthalidone (CTD) versus hydrochlorothiazide (HCTZ):

A

Longer half-life: CTD (~40 hours) versus HCTZ (~4 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Chlorthalidone (CTD) versus hydrochlorothiazide (HCTZ):

A

Chlorthalidone is associated with lower LDL and glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Chlorthalidone (CTD) versus hydrochlorothiazide (HCTZ):

A

Meta-analysis: 19% lower cardiovascular event rate for CTD compared with HCTZ.

Better nighttime BP control. Other beneficial non-BP related effects may be possible.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Orthostatic hypotension management:

A

Goal: focus on the well-being of patient, not achieving a specific BP level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Orthostatic hypotension management:

A

Nondrug: increase fluid and salt intake, avoid getting up quickly or prolonged motionless standing, use of compressive waist-high stockings, raise head of be by 6 to 9 inches, maintain active lifestyle.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Orthostatic hypotension management:

A

Drug options: midodrine, fludrocortisone, and pseudoephedrine

If supine HTN: consider midodrine as needed basis (prn).

If no supine HTN: consider fludrocortisone or midodrine prn. Combination therapy if necessary.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
Sodium glucose transporter-2 (SGLT-2):
canagliflozin (Invokana)
empagliflozin (Jardiance)
empagliflozin/linagliptin (Glyxambi)
empagliflozin/metformin (Synjardy)
A

Expressed in S1 and S2 segments of proximal renal tubule where 90% of glucose reabsorption occurs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
Sodium glucose transporter-2 (SGLT-2):
canagliflozin (Invokana)
empagliflozin (Jardiance)
empagliflozin/linagliptin (Glyxambi)
empagliflozin/metformin (Synjardy)
A

Inhibition of SGLT-2 leads to glucosuria, hence glucose control in diabetics, and weight loss due to glucose-derived calories.

17
Q
Sodium glucose transporter-2 (SGLT-2):
canagliflozin (Invokana)
empagliflozin (Jardiance)
empagliflozin/linagliptin (Glyxambi)
empagliflozin/metformin (Synjardy)
A

Inhibition of SGLT-2 also leads to mild BP reduction, presumably via (osmotic) diuretic effect.

18
Q

SGLT2 is a protein in humans that facilitates glucose reabsorption in the kidney. SGLT2 inhibitors block the reabsorption of glucose in the kidney, increase glucose excretion, and lower blood glucose levels.

A

There is also an increased desire to urinate and the medication is not indicated in patients with type 1 diabetes, or patients with frequent ketones in their blood or urine, severe renal impairment, end stage renal disease or patients receiving dialysis.